1-2 of 2
Mark Rosenthal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S. Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R. Gerritsen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 215–224.
https://doi.org/10.1158/1078-0432.CCR-12-2605
Published: 02 January 2013
View article titled, Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Open the PDF for Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone in another window
Includes: Supplementary data
Journal Articles

A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy

Ian D. Davis, Lynette Kiers, Lachlan MacGregor, Michael Quinn, Joseph Arezzo, Michael Green, Mark Rosenthal, Michael Chia, Michael Michael, Peter Bartley, Leonie Harrison, Michael Daly
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1890–1898.
https://doi.org/10.1158/1078-0432.CCR-04-1655
Published: 08 March 2005
View article titled, A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy
Open the PDF for A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy in another window